ReviewTherapeutic advances in medical oncology2026
Treatment options in platinum-refractory male germ cell cancers: current standards and future directions.
Review in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Germ cell cancers (GCCs) represent the most common malignant tumours among men up to the age of 40 years. GCCs are characterised by high cure rates of >99% for localised stage I disease, but even at advanced metastatic stages, 67%-96% of patients can be cured with multimodal treatment approaches. The high curability owes to an exceptional responsiveness to cisplatin-based chemotherapy. However, about 30% of patients with metastatic disease eventually relapse after first-line multimodality treatment. At first relapse, salvage treatment still cures approximately 50% of patients. Platinum-based chemotherapy remains the standard of care in this setting, administered either as conventional-dose cisplatin-based regimens or as high-dose carboplatin-based combination chemotherapy. Across multiple large retrospective cohorts, high-dose chemotherapy has repeatedly been associated with superior progression-free and overall survival compared with conventional-dose approaches, although definitive prospective evidence is awaited. Patients suffering second or multiple relapses are considered platinum-resistant and face a very dismal prognosis with a life expectancy generally limited to less than 12 months. The mainstay of treatment in this setting is still conventional cytotoxic chemotherapy since no molecularly targeted treatments have shown clinically meaningful activity, to date. However, Claudin-6 (CLDN6)-directed approaches appear the most promising avenue of new treatment options in this situation. In this narrative review, we outline established and emerging treatment opportunities for this rare but challenging clinical scenario of platinum-resistant GCCs. This review provides a focused and up-to-date synthesis of therapeutic options for multiply relapsed, platinum-refractory GCCs, with a particular emphasis on late-line treatment sequencing and emerging biomarker-driven strategies, including CLDN6-directed therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.